No Data
No Data
Is Ionis Pharmaceuticals (NASDAQ:IONS) Weighed On By Its Debt Load?
Ionis Pharmaceuticals: Strategic Partnerships and Financial Flexibility Drive Buy Rating
Express News | Ionis Pharmaceuticals Inc : Leerink Partners Raises Target Price to $55 From $52
Oppenheimer Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating, Raises Target Price to $78
William Blair Maintains Ionis Pharmaceuticals(IONS.US) With Buy Rating
Ionis Pharmaceuticals (IONS) Receives a Buy From William Blair